Maxim Group Reaffirms Buy Rating for Context Therapeutics
Maxim Group maintains its optimistic outlook on Context Therapeutics with a reiterated buy rating and a $4 price target, a 534.92% upside from the current price.
Key Points
- Maxim Group reiterated its buy rating on Context Therapeutics with a $4 price target on June 16, 2026.
- Maxim Group's $4 price target implies 534.92% upside from Context Therapeutics Inc.'s ($CNTX) current $0.63 share price.
- Context Therapeutics shares are trading near $0.68, with a market cap of about $59.7 million and a 52-week range of $0.56 to $3.62.
- Insider buying was reported in February 2026, with several executives acquiring shares, reflecting confidence in the company's prospects.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maxim Group has reiterated its buy rating on Context Therapeutics Inc. (NASDAQ: CNTX) as of June 16, 2026. Analyst Jason McCarthy maintained the optimistic stance with a price target of $4, signaling continued confidence in the company's growth prospects.
Other Institutional Activity in Context Therapeutics
MPM Bioimpact LLC holds 10,679,391 shares valued at approximately $27.98 million, with no change in its position. Nextech Invest, Ltd. also maintained its stake at 7,419,355 shares, worth about $19.44 million. Deep Track Capital, LP similarly held steady with 7,419,355 shares valued at $19.44 million. Soleus Capital Management, L.P. acquired 6,963,141 shares, matching its total holding value of $18.24 million. Meanwhile, Blue Owl Capital Holdings LP reduced its position by 2,343,891 shares, ending with 5,089,015 shares worth about $13.33 million.
Context Therapeutics Inc. Stock Up 64.2%
Shares of Context Therapeutics are trading near $0.68 on the NasdaqCM. The company has a market capitalization of approximately $59.7 million. The stock has experienced a 52-week low of $0.56 and a high of $3.62. It has a 50-day moving average of $2.25 and a 200-day moving average of $1.79. Context Therapeutics exhibits a beta of 1.611, indicating higher volatility compared to the market.
$CNTX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Context Therapeutics Inc.
On February 19, 2026, several executives at Context Therapeutics made significant share purchases. Chief Financial Officer Jennifer Lynn Minai-Azary acquired 275,000 shares, while CEO Martin Lehr purchased 815,000 shares. Chief Medical Officer Karen Deborah Chagin bought 290,000 shares, and Chief Legal Officer Alex Levit bought 270,000 shares. These insider transactions were not under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 16, 2026, Maxim Group maintained its buy rating on Context Therapeutics with a $4 price target. Earlier, on March 24, 2026, D. Boral Capital and Guggenheim both reiterated their buy ratings, setting targets at $9 and $5, respectively. Piper Sandler also maintained a buy rating with a $7 target on the same date. The consensus among analysts is a strong buy, with an average price target of $5.43 based on seven opinions.
About Context Therapeutics
Context Therapeutics Inc. is a healthcare company based in Philadelphia, Pennsylvania, focusing on developing treatments for solid tumors. The company is involved in creating a bispecific antibody, CTIM-76, targeting Claudin 6 (CLDN6) in cancer therapy. Founded in 2015, Context Therapeutics collaborates with Integral Molecular, Inc. and is led by CEO Martin A. Lehr. With a small team of 15 employees, the company aims to advance its clinical-stage biopharmaceutical products.
Bottom Line
Maxim Group's reiteration of a buy rating for Context Therapeutics reflects sustained confidence in the company's potential, despite the stock trading at a low price. The company's focus on innovative cancer treatments and insider buying activity indicates a positive outlook. Investors should note that analyst ratings and price targets are based on past analysis and may not reflect current market conditions.
Get Context Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $CNTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.